AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$UTHR

ROTHBLATT MARTINE A sold $4.7M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $496.06 ($493.22–$501.60, $4.71M total) across 9 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 18, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale may influence short‑term sentiment but is unlikely to alter long‑term fundamentals.

02

Market read

Primary insider sale; modest relevance for traders monitoring UTHR.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 6/10Timing: post‑market 2026‑09‑17

Background

Form 4 filing from SEC EDGAR reporting an insider transaction by United Therapeutics' CEO.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine A. Rothblatt sold 9,500 shares for $4.7M via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

Modest short‑term price dip expected as market digests the sell‑off.

Evidence & confidence

A $4.7M sale by the CEO is material but not large enough to trigger a sharp move; the pre‑arranged plan reduces signaling risk.

Market effects

Sector

May raise concerns for the biotech/therapeutics sector about insider confidence.

Regional

Limited to U.S. markets; no broader regional effect.

Global

Minimal global impact beyond UTHR shareholders.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing under a 10b5‑1 plan, not a bearish signal.

Key entities

  • Company
    United Therapeutics Corp

    NASDAQ‑listed biotech firm (ticker UTHR).

  • Executive
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min